OTC:CRTHF CARsgen Therapeutics (CRTHF) Stock Forecast, Price & News $2.05 0.00 (0.00%) (As of 05/12/2023) Add Compare Share Share Today's Range$2.05▼$2.0550-Day Range$2.05▼$2.0552-Week Range$1.86▼$2.05VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsProfileAnalyst RatingsChartCompetitors About CARsgen Therapeutics (OTC:CRTHF) StockCARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies in China and the U.S. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; and CT011, which is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, which targets CD19 that is in Phase I/II clinical trial for the treatment of B cell non-Hodgkin's lymphoma; CT0180, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma; and CT0181, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in pre-clinical stage for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in pre-clinical stage for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJ-C2112, an epidermal growth factor receptor/variant III of epidermal growth factor receptor, which is in pre-clinical stage for the treatment of glioblastoma; and KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors. Further, it is developing AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company was founded in 2014 and is headquartered in Shanghai, China.Read More CRTHF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRTHF Stock News HeadlinesMarch 22, 2022 | financialpost.comUK Stocks-Factors to watch on March 22See More Headlines Receive CRTHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CARsgen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTC Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTC:CRTHF CUSIPN/A CIKN/A Webcrestnicholson.com Phone44.19.32580555FaxN/AEmployees525Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Zonghai Li M.D. (Age 48)Ph.D., Co-Founder, CEO, CSO & Chairman Comp: $273.92kDr. Huamao Wang Ph.D. (Age 46)Co-Founder, COO & Exec. Director Comp: $293.57kDr. Hua Jiang (Age 44)Exec. Director Comp: $316.25kDr. Hong Ma (Age 51)Sr. VP of Clinical Devel. Dr. Leigh Hsu (Age 52)Sr. VP of Bus. Devel. Ms. Caihua JiangSr. VP of QualityDr. Raffaele Baffa M.D. (Age 63)Ph.D., Chief Medical Officer Dr. Sylvie Peltier (Age 60)Sr. VP of Global Regulatory Affairs Mr. Richard John Daly M.B.A. (Age 62)Pres of CARsgen Therapeutics Corp. Mr. Wing Yat Lui (Age 33)Company Sec. More ExecutivesKey Competitors3SBioOTCMKTS:TRSBF60 Degrees Pharmaceuticals, Inc. WarrantNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAgentixOTCMKTS:AGTXView All Competitors CRTHF Stock - Frequently Asked Questions Should I buy or sell CARsgen Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CARsgen Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRTHF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRTHF, but not buy additional shares or sell existing shares. View CRTHF analyst ratings or view top-rated stocks. How have CRTHF shares performed in 2023? CARsgen Therapeutics' stock was trading at $2.05 at the beginning of 2023. Since then, CRTHF shares have decreased by 9.3% and is now trading at $1.86. View the best growth stocks for 2023 here. What is CARsgen Therapeutics' stock symbol? CARsgen Therapeutics trades on the OTC under the ticker symbol "CRTHF." How do I buy shares of CARsgen Therapeutics? Shares of CRTHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CARsgen Therapeutics' stock price today? One share of CRTHF stock can currently be purchased for approximately $1.86. How many employees does CARsgen Therapeutics have? The company employs 525 workers across the globe. How can I contact CARsgen Therapeutics? CARsgen Therapeutics' mailing address is Crest House, Chertsey, Surrey KT16. The official website for the company is crestnicholson.com. The company can be reached via phone at 44.19.32580555. This page (OTC:CRTHF) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARsgen Therapeutics Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.